DARE (Dare Bioscience) Research & Development: $3.89 Mil (TTM As of Mar. 2026)


DARE Dare Bioscience Inc DARE
23 GF Score
Price $2.08
! 4 Warning Signs
View Full Analysis

What is Dare Bioscience Research & Development?

Dare Bioscience DARE +4.00% 23 Research & Development is $3.89 Mil as of Mar. 2026. GuruFocus rates DARE with a GF Score™ of 23/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Dare Bioscience's Research & Development for the three months ended in Mar. 2026 was $0.66 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $3.89 Mil.


Dare Bioscience  (NAS:DARE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Dare Bioscience Research & Development Related Terms


Dare Bioscience Research & Development Historical Data

* Premium members only.

The historical data trend for Dare Bioscience's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dare Bioscience Research & Development Chart

Dare Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.62 30.04 21.54 14.31 5.52

Dare Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.30 1.43 1.18 0.62 0.66
DARE
23GF Score
Dare Bioscience Inc DARE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dare Bioscience Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $3.89 Mil mean?
Dare Bioscience (DARE) has a Research & Development of $3.89 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Dare Bioscience and its competitors.
Is Dare Bioscience's Research & Development too high?
Dare Bioscience's current Research & Development is $3.89 Mil. Overall, Dare Bioscience has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Dare Bioscience's Research & Development compare to TVGN and LITS?
Dare Bioscience's Research & Development of $3.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Dare Bioscience and its competitors. Dare Bioscience's current Research & Development is $3.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dare Bioscience stock overvalued right now?
Dare Bioscience (DARE) has a current Research & Development of $3.89 Mil. The current Research & Development is $3.89 Mil. Dare Bioscience's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Dare Bioscience (DARE), the current Research & Development is $3.89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dare Bioscience Business Description

Address 3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
23GF Score

Get the complete analysis for DARE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price